This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Orlistat in prediabetes

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Orlistat in Prediabetes

NICE suggest that a clinician should use clinical judgement on whether to offer orlistat to people with a BMI of 28.0 kg/m2 or more, as part of an overall plan for managing obesity ( take into account the person's risk and the level of weight loss and lifestyle change required to reduce this risk)

Duration:

  • review the use of orlistat after 12 weeks
    • if the person has not lost at least 5% of their original body weight, use clinical judgement to decide whether to stop the orlistat
    • note however, as with adults who have type 2 diabetes, those at high risk of the condition may lose weight more slowly than average, so less strict goals may be appropriate

  • only use orlistat for more than 12 months (usually for weight maintenance) after discussing the potential benefits, limitations and side effects with the person concerned

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.